New weapons in the fight against cancer
The increase in our knowledge and understanding of molecular pathways is leading to the identification of novel and appealing targets in oncology
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The increase in our knowledge and understanding of molecular pathways is leading to the identification of novel and appealing targets in oncology
New findings pose a question on optimal duration of trastuzumab therapy for women with HER2-positive early breast cancer; the subset analysis may give an answer
Spinal cord compression, pathological fracture and other skeletal-related events (SREs) feature prominently in patients with metastatic castration-resistant prostate cancer (mCRPC). The bisphosphonate, zoledronate, is widely, though not universally, regarded as a standard treatment to reduce the risk of SREs in these patients. However, new drugs are emerging suggesting that we may soon be able to offer a better standard of care for the prevention of SREs and metastatic bone pain
Following on from the positive data reported by Dr Alice Shaw on the Phase 3 trial of crizotinib as second-line therapy for patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), findings from the European Thoracic Oncology Platform Lungscape Project, which is evaluating the prevalence of ALK positivity in resected stage I-III lung adenocarcinomas in Europe, were met with great interest.
Findings confirm the current standard duration of adjuvant trastuzumab for women with HER2-positive early breast cancer
Findings from the primary analysis of the randomized Phase 3, European intergroup PETACC8 trial, presented at ESMO 2012 by Dr Julien Taieb of the Georges Pompidou European Hospital, Paris, France, showed that the addition of cetuximab to standard adjuvant FOLFOX4 chemotherapy regimen offers no benefit to patients with resected stage III, KRAS wild-type (wt) colon cancer.
Comparing two bevacizumab-containing regimens as first-line therapy for HER2 negative metastatic breast cancer
Results of the randomized BEBYP study
An educational session explored a range of options that clinicians could adopt to manage cancer patients where the primary tumour site is unknown.
Find the most common oncology abbreviations.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.